Management of transfusional iron overload – differential properties and efficacy of iron chelating agents
Open Access
- 1 September 2011
- journal article
- review article
- Published by Taylor & Francis in Journal of Blood Medicine
- Vol. 2, 135-149
Abstract
Regular red cell transfusion therapy ameliorates disease-related morbidity and can be lifesaving in patients with various hematological disorders. Transfusion therapy, however, causes progressive iron loading, which, if untreated, results in endocrinopathies, cardiac arrhythmias and congestive heart failure, hepatic fibrosis, and premature death. Iron chelation therapy is used to prevent iron loading, remove excess accumulated iron, detoxify iron, and reverse some of the iron-related complications. Three chelators have undergone extensive testing to date: deferoxamine, deferasirox, and deferiprone (although the latter drug is not currently licensed for use in North America where it is available only through compassionate use programs and research protocols). These chelators differ in their modes of administration, pharmacokinetics, efficacy with regard to organ-specific iron removal, and adverse-effect profiles. These differential properties influence acceptability, tolerability and adherence to therapy, and, ultimately, the effectiveness of treatment. Chelation therapy, therefore, must be individualized, taking into account patient preferences, toxicities, ongoing transfusional iron intake, and the degree of cardiac and hepatic iron loading.Keywords
This publication has 134 references indexed in Scilit:
- Safety and Efficacy of Combined Chelation Therapy with Deferasirox and Deferoxamine in a Gerbil Model of Iron OverloadActa Haematologica, 2008
- Effect of Food, Type of Food, and Time of Food Intake on Deferasirox Bioavailability: Recommendations for an Optimal Deferasirox Administration RegimenThe Journal of Clinical Pharmacology, 2008
- Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunctionJournal of Cardiovascular Magnetic Resonance, 2008
- Relative response of patients with myelodysplastic syndromes and other transfusion‐dependent anaemias to deferasirox (ICL670): a 1‐yr prospective studyEuropean Journal of Haematology, 2007
- Magnetic resonance imaging measurement of iron overloadCurrent Opinion in Hematology, 2007
- A randomised comparison of deferasiroxversusdeferoxamine for the treatment of transfusional iron overload in sickle cell diseaseBritish Journal of Haematology, 2006
- Rapid removal of excessive iron with daily, high-dose intravenous chelation therapyThe Journal of Pediatrics, 1989
- Growth and sexual maturation in thalassemia majorThe Journal of Pediatrics, 1985
- Magnetic-Susceptibility Measurement of Human Iron StoresNew England Journal of Medicine, 1982
- Hereditary HemochromatosisNew England Journal of Medicine, 1979